Neurocrine Biosciences, Inc. (NBIX), Friday announced a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, evaluating the long-term efficacy, safety and tolerability of INGREZZA in adults with tardive dyskinesia, a movement disorder.
The open-label study found that the patients treated with 40 mg dose of once-daily INGREZZA capsules experienced clinically meaningful improvements in tardive dyskinesia symptoms.
Of the total participants, 90 percent on continuous INGREZZA 40 mg treatment showed "much improved" or "very much improved" at Week 48 per clinician assessment and patient self-report.
Moreover, 90 percent of those completing 48 weeks met the Abnormal Involuntary Movement Scale response threshold. Similarly, patients who reduced their dose from 80 mg to 40 mg for tolerability reasons achieved similar therapeutic benefits.
Currently, NBIX is trading at $137.80, up 0.20 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.